Autoimmune And Rheumatic Diseases

WASHINGTON — Preexisting autoimmune diseases do not increase mortality risk in patients treated with immune checkpoint inhibitors for cancer, according to data presented at ACR Convergence 2024.

WASHINGTON — The correlation between autoantibodies and new-onset autoimmune disease in individuals with long COVID symptoms remains “controversial,” according to a speaker at ACR Convergence 2024.

I am thrilled to introduce a guest editorial that explores the humanity of our field, written by Mike Schweitz, MD.

From 2011 to 2019, the proportion of rheumatologists who reported using in-house pharmacies exploded, from 4% to 22% — a more than fivefold increase.

WASHINGTON — Addressing burnout in rheumatology will require attention to personal exhaustion and depersonalization, as well as systemic business-of-medicine issues, according to a speaker at ACR Convergence 2024.

WASHINGTON — Among patients with systemic autoimmune rheumatic diseases, circulating interleukin-18 levels were lower in those with long COVID vs. those without, according to data presented at ACR Convergence 2024.

WASHINGTON — Biosimilar infliximab use is significantly more common among new users vs. those who started with the originator, and particularly less likely among Medicare beneficiaries, according to data presented at ACR Convergence 2024.

WASHINGTON — Practices that join the American College of Rheumatology’s RISE registry report “doubled to tripled” rates of improvement in rheumatoid arthritis function and disease activity assessment, according to data.

WASHINGTON — Inebilizumab is safe and effective in IgG4-related disease, significantly reducing the chance of flare through 52 weeks compared with placebo, according to data presented at ACR Convergence 2024.

WASHINGTON — Whether through advocacy on Capitol Hill, helping women advance their careers, or addressing the rheumatology workforce shortage, American College of Rheumatology President Deborah Dyett Desir, MD, believes in “giving back.”